The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade
- PMID: 8995446
- DOI: 10.1074/jbc.272.2.1368
The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade
Abstract
Mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) and MKP-2 are two members of a recently described family of dual specificity phosphatases that are capable of dephosphorylating p42/p44MAPK. Overexpression of MKP-1 or MKP-2 inhibits MAP kinase-dependent intracellular signaling events and fibroblast proliferation. By using specific antibodies that recognize endogenous MKP-1 and MKP-2 in CCL39 cells, we show that MKP-1 and MKP-2 are not expressed in quiescent cells, but are rapidly induced following serum addition, with protein detectable as early as 30 min (MKP-1) or 60 min (MKP-2). Serum induction of MKP-1 and MKP-2 is sustained, with protein detectable up to 14 h after serum addition. Induction of MKP-1 and, to a lesser extent, MKP-2 temporally correlates with p42/p44MAPK inactivation. To analyze the contribution of the MAP kinase cascade to MKP-1 and MKP-2 induction, we examined CCL39 cells transformed with either v-ras or a constitutively active direct upstream activator of MAP kinase, mitogen-activated protein kinase kinase-1 (MKK-1; MKK-1(SD/SD) mutant). In both cell models, MKP-1 and MKP-2 are constitutively expressed, with MKP-2 being prevalent. In addition, in CCL39 cells expressing an estradiol-inducible deltaRaf-1::ER chimera, activation of Raf alone is sufficient to induce MKP-1 and MKP-2. The role of the MAP kinase cascade in MKP induction was highlighted by the MKK-1 inhibitor PD 098059, which blunted both the activation of p42/p44MAPK and the induction of MKP-1 and MKP-2. However, the MAP kinase cascade is not absolutely required for the induction of MKP-1, as this phosphatase, but not MKP-2, was induced to detectable levels by agents that stimulate protein kinases A and C. Thus, activation of the p42/p44MAPK cascade promotes the induction of MKP-1 and MKP-2, which may then attenuate p42/p44MAPK-dependent events in an inhibitory feedback loop.
Similar articles
-
Feedback regulation of Raf-1 and mitogen-activated protein kinase (MAP) kinase kinases 1 and 2 by MAP kinase phosphatase-1 (MKP-1).J Biol Chem. 1998 Jan 16;273(3):1788-93. doi: 10.1074/jbc.273.3.1788. J Biol Chem. 1998. PMID: 9430728
-
Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.J Biol Chem. 1996 Aug 23;271(34):20608-16. doi: 10.1074/jbc.271.34.20608. J Biol Chem. 1996. PMID: 8702807
-
Cyclic AMP inhibitors inhibits PDGF-stimulated mitogen-activated protein kinase activity in rat aortic smooth muscle cells via inactivation of c-Raf-1 kinase and induction of MAP kinase phosphatase-1.Cell Signal. 1997 May-Jun;9(3-4):323-8. doi: 10.1016/s0898-6568(96)00193-3. Cell Signal. 1997. PMID: 9218135
-
Regulation of innate immune response by MAP kinase phosphatase-1.Cell Signal. 2007 Jul;19(7):1372-82. doi: 10.1016/j.cellsig.2007.03.013. Epub 2007 Apr 20. Cell Signal. 2007. PMID: 17512700 Free PMC article. Review.
-
Mitogen activated protein kinase phosphatases and cancer.Cancer Biol Ther. 2010 Mar 1;9(5):337-40. doi: 10.4161/cbt.9.5.11217. Epub 2010 Mar 17. Cancer Biol Ther. 2010. PMID: 20139719 Free PMC article. Review.
Cited by
-
MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution.J Clin Invest. 2024 Mar 21;134(10):e172826. doi: 10.1172/JCI172826. J Clin Invest. 2024. PMID: 38512415 Free PMC article.
-
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.Signal Transduct Target Ther. 2023 Dec 18;8(1):455. doi: 10.1038/s41392-023-01705-z. Signal Transduct Target Ther. 2023. PMID: 38105263 Free PMC article. Review.
-
Navigating the ERK1/2 MAPK Cascade.Biomolecules. 2023 Oct 20;13(10):1555. doi: 10.3390/biom13101555. Biomolecules. 2023. PMID: 37892237 Free PMC article. Review.
-
Involvement of clusterin expression in the refractory response of pancreatic cancer cells to a MEK inhibitor.Cancer Sci. 2023 May;114(5):2189-2202. doi: 10.1111/cas.15735. Epub 2023 Feb 9. Cancer Sci. 2023. PMID: 36694355 Free PMC article.
-
Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.Cancer Commun (Lond). 2023 Jan;43(1):42-74. doi: 10.1002/cac2.12377. Epub 2022 Oct 31. Cancer Commun (Lond). 2023. PMID: 36316602 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous